These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 36974332)

  • 41. Mu-opioid and noradrenergic α(2)-adrenoceptor contributions to the effects of tapentadol on spinal electrophysiological measures of nociception in nerve-injured rats.
    Bee LA; Bannister K; Rahman W; Dickenson AH
    Pain; 2011 Jan; 152(1):131-139. PubMed ID: 21187272
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Effectiveness and safety of tapentadol prolonged release for severe, chronic low back pain with or without a neuropathic pain component: results of an open-label, phase 3b study.
    Steigerwald I; Müller M; Davies A; Samper D; Sabatowski R; Baron R; Rozenberg S; Szczepanska-Szerej A; Gatti A; Kress HG
    Curr Med Res Opin; 2012 Jun; 28(6):911-36. PubMed ID: 22443293
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Tapentadol hydrochloride: a centrally acting oral analgesic.
    Wade WE; Spruill WJ
    Clin Ther; 2009 Dec; 31(12):2804-18. PubMed ID: 20110020
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Miotic and subject-rated effects of therapeutic doses of tapentadol, tramadol, and hydromorphone in occasional opioid users.
    Stoops WW; Glaser PE; Rush CR
    Psychopharmacology (Berl); 2013 Jul; 228(2):255-62. PubMed ID: 23430163
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Tapentadol in Cancer Patients with Neuropathic Pain: A Comparison of Methadone, Oxycodone, Fentanyl, and Hydromorphone.
    Takemura M; Niki K; Okamoto Y; Matsuda Y; Omae T; Takagi T; Ueda M
    Biol Pharm Bull; 2021; 44(9):1286-1293. PubMed ID: 34471056
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Acute administration of tramadol and tapentadol at effective analgesic and maximum tolerated doses causes hepato- and nephrotoxic effects in Wistar rats.
    Barbosa J; Faria J; Leal S; Afonso LP; Lobo J; Queirós O; Moreira R; Carvalho F; Dinis-Oliveira RJ
    Toxicology; 2017 Aug; 389():118-129. PubMed ID: 28689766
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Tapentadol. Acute or chronic pain: no therapeutic advance.
    Prescrire Int; 2014 May; 23(149):121-4. PubMed ID: 24926510
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Comparative study of dezocine, pentazocine and tapentadol on antinociception and physical dependence.
    Ahsan MZ; Zhao MJ; Shoaib RM; Zhang Y; Wang YX
    Life Sci; 2021 Nov; 285():119996. PubMed ID: 34597607
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Does 'Strong Analgesic' Equal 'Strong Opioid'? Tapentadol and the Concept of 'µ-Load'.
    Raffa RB; Elling C; Tzschentke TM
    Adv Ther; 2018 Oct; 35(10):1471-1484. PubMed ID: 30206823
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Monoaminergic opioids: which one should we choose?].
    Roulet L; Rollason V; Desmeules J; Piguet V
    Rev Med Suisse; 2021 Jun; 17(744):1218-1223. PubMed ID: 34160919
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Ready conversion of patients with well-controlled, moderate to severe, chronic malignant tumor-related pain on other opioids to tapentadol extended release.
    Imanaka K; Tominaga Y; Etropolski M; Ohashi H; Hirose K; Matsumura T
    Clin Drug Investig; 2014 Jul; 34(7):501-11. PubMed ID: 24906437
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Tapentadol extended-release for treatment of chronic pain: a review.
    Vadivelu N; Timchenko A; Huang Y; Sinatra R
    J Pain Res; 2011; 4():211-8. PubMed ID: 21887118
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Direct conversion from tramadol to tapentadol prolonged release for moderate to severe, chronic malignant tumour-related pain.
    Kress HG; Koch ED; Kosturski H; Steup A; Karcher K; Dogan C; Etropolski M; Eerdekens M
    Eur J Pain; 2016 Oct; 20(9):1513-8. PubMed ID: 27062079
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Tapentadol prolonged release versus strong opioids for severe, chronic low back pain: results of an open-label, phase 3b study.
    Gálvez R; Schäfer M; Hans G; Falke D; Steigerwald I
    Adv Ther; 2013 Mar; 30(3):229-59. PubMed ID: 23475406
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Unique pharmacology of tapentadol for treating acute and chronic pain.
    Knezevic NN; Tverdohleb T; Knezevic I; Candido KD
    Expert Opin Drug Metab Toxicol; 2015; 11(9):1475-92. PubMed ID: 26215077
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Comparative metabolism of tramadol and tapentadol: a toxicological perspective.
    Barbosa J; Faria J; Queirós O; Moreira R; Carvalho F; Dinis-Oliveira RJ
    Drug Metab Rev; 2016 Nov; 48(4):577-592. PubMed ID: 27580162
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Opioid and noradrenergic contributions of tapentadol in experimental neuropathic pain.
    Meske DS; Xie JY; Oyarzo J; Badghisi H; Ossipov MH; Porreca F
    Neurosci Lett; 2014 Mar; 562():91-6. PubMed ID: 23969300
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Safety of tapentadol compared with other opioids in chronic pain treatment: network meta-analysis of randomized controlled and withdrawal trials.
    Freynhagen R; Elling C; Radic T; Sohns M; Liedgens H; James D; McCool R; Edwards M
    Curr Med Res Opin; 2021 Jan; 37(1):89-100. PubMed ID: 33032466
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Tapentadol shows lower intrinsic efficacy at µ receptor than morphine and oxycodone.
    Manandhar P; Connor M; Santiago M
    Pharmacol Res Perspect; 2022 Feb; 10(1):e00921. PubMed ID: 35084120
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Tapentadol: an initial analysis.
    Prommer EE
    J Opioid Manag; 2010; 6(3):223-6. PubMed ID: 20642251
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.